• 1. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 4. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

Research Brief on 7-(2-methoxyethyl)-1,3-dimethyl-8-(piperidin-1-yl)methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione (CAS: 797028-16-1)

In recent years, the compound 7-(2-methoxyethyl)-1,3-dimethyl-8-(piperidin-1-yl)methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione (CAS: 797028-16-1) has garnered significant attention in the field of chemical biology and pharmaceutical research. This xanthine derivative, with its unique structural modifications, has shown promising potential in various therapeutic applications, particularly in the modulation of adenosine receptors and related pathways. The following research brief synthesizes the latest findings on this compound, highlighting its pharmacological properties, mechanisms of action, and potential clinical applications.

Recent studies have focused on the compound's interaction with adenosine receptors, specifically the A_2A and A_2B subtypes, which play critical roles in inflammation, immune response, and cardiovascular function. Structural analysis reveals that the 2-methoxyethyl and piperidin-1-ylmethyl substitutions enhance the compound's binding affinity and selectivity for these receptors. In vitro assays demonstrated potent antagonistic activity, with IC₅₀ values in the nanomolar range, suggesting its utility as a lead compound for developing novel anti-inflammatory and neuroprotective agents.

In vivo studies using rodent models have further elucidated the compound's pharmacokinetic profile and therapeutic efficacy. Oral administration of 7-(2-methoxyethyl)-1,3-dimethyl-8-(piperidin-1-yl)methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione exhibited favorable bioavailability and brain penetration, making it a candidate for treating central nervous system disorders such as Parkinson's disease and ischemic stroke. Notably, the compound's ability to cross the blood-brain barrier without significant off-target effects underscores its potential for clinical translation.

Mechanistic investigations have revealed that the compound's therapeutic effects are mediated through the inhibition of pro-inflammatory cytokine release and the modulation of glial cell activation. Transcriptomic and proteomic analyses highlighted downstream effects on NF-κB and MAPK signaling pathways, providing a molecular basis for its anti-inflammatory and neuroprotective properties. These findings align with emerging trends in precision medicine, where targeting specific receptor subtypes can minimize adverse effects and improve therapeutic outcomes.

Despite these advancements, challenges remain in optimizing the compound's pharmacokinetic and safety profiles. Recent toxicology studies reported dose-dependent hepatotoxicity in long-term exposure models, necessitating further structural refinements. Computational modeling and structure-activity relationship (SAR) studies are underway to identify derivatives with improved safety margins while retaining high receptor affinity. Collaborative efforts between academia and industry are expected to accelerate the development of next-generation analogs.

In conclusion, 7-(2-methoxyethyl)-1,3-dimethyl-8-(piperidin-1-yl)methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione represents a promising scaffold for drug discovery, particularly in inflammation and neurology. Its unique pharmacological profile and mechanistic insights position it as a valuable tool for both basic research and therapeutic development. Future studies should focus on clinical validation and addressing translational hurdles to unlock its full potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)